News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY) Schizophrenia Drug And Clinical Trial Transparency


1/23/2014 8:07:35 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Roche announced today that its Phase 3 drug for schizophrenia, bitopertin, has failed two phase 3 studies. Bitopertin is being studied to determine if it can help schizophrenia patients with their “negative” symptoms such as lack of emotion and poor social skills. Unfortunately for Roche and schizophrenics, the first two studies that have been completed show that bitopertin is no different from placebo in improving negative symptoms after 24 weeks.

Hey, check out all the research scientist jobs. Post your resume today!

Read at Forbes

comments powered by Disqus
Forbes
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES